Parse Biosciences Announces Acquisition by QIAGEN
Seattle – November 4, 2025 – Cooley advised Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research, on its definitive agreement to be fully acquired by QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA). QIAGEN will fully acquire Parse for an upfront payment of approximately $225 million in cash, with Parse equity holders eligible for additional milestone payments of up to $55 million based on the achievement of targets over a multiyear period.
Lawyers Colleen Badgley, Miguel Vega, Heather Harrington, Edward (Teddy) Nimetz, Lucy Bauer, Cameron Irwin, Charity Williams, Charles Haley, Jonathan Rivinus and Emily Mason led the Cooley team advising Parse Biosciences.
Cooley has worked with Parse Biosciences since its inception and across all financing rounds.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related services
-
Mergers and Acquisitions
-
Life Sciences and Healthcare
-
Emerging Companies
-
Private Equity
-
Life Sciences Corporate Partnering and Licensing
-
Technology Transactions
-
Compensation and Benefits
-
Tax
-
Commercial Litigation
-
Antitrust and Competition
-
Cyber/Data/Privacy
-
CFIUS
-
Trademark, Copyright and Advertising
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.